SCHEMBL1103030

SCHEMBL1103030

Cc1cc(C)cc(-c2c3ccccc3c(-c3ccccc3)c3ncccc23)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.42
HSP90AA1 P07900 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TACR1 P25103 4/20 0.40
COMT P21964 1/20 0.40
CKS1B P61024 2/20 0.40
SKP2 Q13309 2/20 0.40
CCR1 P32246 1/20 0.39
CCR8 P51685 1/20 0.39
TOP1 P11387 2/20 0.39
PSMD14 O00487 2/20 0.38
COPS5 Q92905 2/20 0.38
GLO1 Q04760 1/20 0.36
SLC6A2 P23975 1/20 0.36
HTT P42858 1/20 0.36
PSMB5 P28074 1/20 0.36
ACHE P22303 1/20 0.36
GRM4 Q14833 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102841 0.95 L3MBTL1 (0.46) NPC1HSP90AA1L3MBTL1TACR1COMT
SCHEMBL1103024 0.90 COMT (0.49) NPC1HSP90AA1L3MBTL1TACR1COMT
SCHEMBL1103016 0.89 ENPP1 (0.43) NPC1HSP90AA1L3MBTL1CCR1CCR8
SCHEMBL1102829 0.87 COMT (0.51) NPC1HSP90AA1L3MBTL1TACR1COMT
SCHEMBL1102824 0.87 L3MBTL1 (0.43) NPC1HSP90AA1L3MBTL1CKS1BSKP2
SCHEMBL1103019 0.86 ACHE (0.46) NPC1HSP90AA1L3MBTL1TACR1COMT
SCHEMBL1102831 0.86 ENPP1 (0.45) NPC1HSP90AA1L3MBTL1COMTCCR1
SCHEMBL1102944 0.85 TOP1 (0.39) NPC1HSP90AA1L3MBTL1CKS1BSKP2
SCHEMBL1103109 0.85 L3MBTL1 (0.42) NPC1HSP90AA1L3MBTL1CKS1BSKP2
SCHEMBL1103115 0.85 L3MBTL1 (0.42) NPC1HSP90AA1L3MBTL1CKS1BSKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 NPC1 1582/4885HSP90AA1 4884/4885L3MBTL1 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.